RAF1 and non-small cell lung carcinoma: Additionally, a novel RAF dimer selective inhibitor, lifirafenib (BGB-283), tested in a phase I clinical study, demonstrated promising antitumor activity in KRASG12-mutant NSCLC patients [70].